Press "Enter" to skip to content

Month: February 2018

Sucampo present lubiprostone phase 3 trial data in Japanese CIC in DDW 2011 Sucampo Pharmaceuticals.

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC in DDW 2011 Sucampo Pharmaceuticals, Inc. and Abbott today reported data from a stage 3 medical efficacy trial in 124 Japanese chronic idiopathic constipation patients and also from a phase 3 long-term safety trial within an additional 209 Japanese CIC sufferers. The objective of the studies was to confirm the treatment effect and basic safety account of lubiprostone capsules in Japanese CIC individuals. The principal endpoint of the efficacy trial, a differ from baseline in the amount of spontaneous bowel movements at the end of the first week of treatment, was fulfilled by the patients taking 24-mcg lubiprostone twice a day time . Continue reading Sucampo present lubiprostone phase 3 trial data in Japanese CIC in DDW 2011 Sucampo Pharmaceuticals.

Aiming medicine and counselling at the precise epilepsy syndrome will lead to best management.

Driving restrictions have the greatest effect on psychosocial function often. Knowledge of the most commonly used antiepileptic medications is essential in guiding therapy. There are special needs according to gender and age. A small group of refractory patients shall benefit from referral to specialist epilepsy treatment centers.. A practical guidebook to the management of epilepsy Methods to treating epilepsy are being increasingly refined as more is understood about the various syndromes and their response to medicines. Aiming medicine and counselling at the precise epilepsy syndrome will lead to best management. The prognosis of epilepsy varies widely and depends on the specific epilepsy syndrome. Continue reading Aiming medicine and counselling at the precise epilepsy syndrome will lead to best management.